Flu season ends with a whisper, not a bang.

Published Date: 14 Mar 2023

The 2022-2023 flu season is on the edge of life which has been predicted for half of January and most of February.

Read Full News

Latest News

How New Therapies Are Reshaping HER2+ Breast Cancer

Once a uniformly aggressive subtype, HER2+ breast cancer is now a proving ground for the most innovative therapies in oncology.

Deep Dive: Treatment or Surgery First in Pancreatic Cancer?

Pancreatic cancer's neoadjuvant debate is no longer about whether systemic therapy matters. It is about when to give it.

Fecal Transplant Offers No Clear Benefit in IBS

Fecal microbiota transplantation offers no clear benefit in reducing symptoms of irritable bowel syndrome, a meta-analysis finds.

Should Type 2 Patients Not on Insulin Use Glucose Monitors?

While research shows some blood glucose benefits, perhaps the biggest benefit comes from lifestyle changes.

AAP Guidance Seeks to Prevent Iron Deficiency Anemia

The new recommendations include universal screening for teens girls, who are at a high risk for iron deficiency and iron deficiency anemia.

PSMA-PET-CT May Allow Some Men to Skip Prostate Biopsy

Phase 3 data suggest PSMA-PET-CT could reduce unnecessary prostate biopsies in selected high-risk men, though longer follow-up is needed.

Todays Updates

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Todays Updates

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Latest News

Once a uniformly aggressive subtype, HER2+ breast cancer is now a proving ground for the most innovative therapies in oncology.

Pancreatic cancer's neoadjuvant debate is no longer about whether systemic therapy matters. It is about when to give it.

Fecal microbiota transplantation offers no clear benefit in reducing symptoms of irritable bowel syndrome, a meta-analysis finds.
HTTP error: 503

The new recommendations include universal screening for teens girls, who are at a high risk for iron deficiency and iron deficiency anemia.

Phase 3 data suggest PSMA-PET-CT could reduce unnecessary prostate biopsies in selected high-risk men, though longer follow-up is needed.

News All Time

Micro- and Nanoplastics: A Multiorgan Health Threat

Once present in the body, microplastics and nanoplastics can disrupt biological barriers and contribute to diseases impacting the gastrointestinal system and beyond.

Nasal Strips: Fancy Tape or Medical Miracle?

Nasal strips flood your feed and promise better sleep. Dr Labos investigates whether nasal strips are worth the hype — or just a very convincing placebo.

Deep Dive: Is Bariatric Surgery Over?

New obesity drugs are posting surgical-scale weight-loss numbers. Is the gap closing, or are we mistaking early results for the final answer?

Parkinson’s Treatment: Are Dopamine Agonists Fading?

New discussion around Parkinson’s treatment is putting dopamine agonists under the spotlight, with clinicians balancing motor benefits against behavioral side effects.

Does Liso-Cel Offer Long-Term Survival Benefits in R/R LBCL?

Researchers report the 5-year survival outcomes with lisocabtagene maraleucel in heavily pretreated patients with relapsed or refractory LBCL in the TRANSCEND study.

Treat or Wait, New Data on Asymptomatic Kidney Stones

Actively treating asymptomatic kidney stones is associated with lower odds of later recurrence and the need for surgery.

Australia’s New Lung Cancer Screening Enjoys High Uptake

The first year of Australia’s lung cancer screening program appears to be a success, with high uptake among its target population of heavy smokers.

Prostate Care: Quick Relief vs Retreatment

From steam injections to drug-coated balloons, the options for treating an enlarged prostate are growing fast.

Positive Topline Results for Novel LSD Formulation in MDD

A single dose of the LSD-based therapy DT120 produced rapid antidepressant effects that remained significant through 12 weeks in a pivotal phase 3 trial of major depressive disorder.

The $5 Million Doctor

1 in 5 doctors say their family’s net worth has crossed $5 million.
HTTP error: 503

Trofinetide Approved for Rett Syndrome After Reexamination

The EMA reverses its previous decision and grants marketing authorization to the world’s first drug specifically approved for treating the syndrome.

Pfizer Trial Backs Paxlovid Dose for High-Risk Children

A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.

New Parkinson’s Drug Combines Immediate and Slow Release

The EMA approves a new formulation of a levodopa-carbidopa combination to treat moderate-to-severe motor fluctuations in patients with Parkinson’s disease.

Is Creatine for Brain Health Worth a Try?

Research on creatine supplementation has moved from the gym to the brain lab, leading neurologist Heidi Moawad to review the data on creatine’s potential for improving cognitive health.

S1 Episode 2: Is Alcohol the Missing Piece in Your MASLD Workup?

Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.

Recommended News For You

New policy review highlights the importance of health-related quality of life in advanced cancer

Higher Binge Drinking Rates Linked to New Cannabis Laws.

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

Recent Rise in Early-Onset Solid Tumors Is Associated with Accelerated Aging.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Active Surveillance Lawsuits; More Eligibility for Studies; Biosimilars Make News.

Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma

Recommended Articles For You

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer 

Intrapancreatic Fat, Pancreatitis, and Cancer: Role of Cancer-Associated Fibroblasts 

Clinical Frameworks in Oncology and Quality Improvement 

The Cutting-Edge of Phlebectomy: Redefining Vein Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In cases of metastatic or recurrent head and neck cancer, gene-guided immunotherapy falls short.

2.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

3.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

4.

An understudied type of breast cancer poses a lurking threat

5.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

1.

Next-Gen Cancer Therapies: Radiopharmaceuticals, Immuno-Oncology, and Biologic Breakthroughs

2.

Seeing Beyond the Pink Ribbon: AI's New Battle Against Breast Cancer

3.

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting 

4.

Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization

5.

The Future of Oncology: Innovations Every Doctor Should Know

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

2.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion

4.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot